Zanubrutinib
FDA-approved product (capsule, oral), marketed as Brukinsa.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Cancer
- Mantle cell lymphoma
- Neoplasm
- Waldenstrom macroglobulinemia
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Bruton's tyrosine kinase (btk) inhibitors
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA53.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli39.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae25.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis51.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Zanubrutinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- UrsodiolExisting use: Biliary liver cirrhosis, Primary biliary cirrhosis69.2% AI-predicted activityagainst MRSA50+ registered studies
- OlaparibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 9 more69.2% AI-predicted activityagainst MRSA50+ registered studies
- Ganirelix AcetateExisting use: Female infertility, Positive regulation of ovulation, Reproductive Techniques, Assisted69.1% AI-predicted activityagainst MRSA50+ registered studies
- DanicopanExisting use: Acquired paroxysmal nocturnal hemoglobinuria, Hemoglobinuria, Paroxysmal, Hemolysis68.7% AI-predicted activityagainst MRSA30 registered studies
- Simeprevir SodiumExisting use: Chronic hepatitis C virus infection68.6% AI-predicted activityagainst MRSANo documented evidence found
- Lanreotide AcetateExisting use: Acromegaly, Carcinoid syndrome68.3% AI-predicted activityagainst MRSA50+ registered studies
- Cholic AcidExisting use: Abnormality of the gastrointestinal tract, Inborn errors of metabolism, Liver disease and 1 more68.0% AI-predicted activityagainst MRSA50+ registered studies
- EptifibatideExisting use: Acute coronary syndrome, Acute myocardial infarction, Intermediate coronary syndrome and 2 more67.8% AI-predicted activityagainst MRSA35 registered studies
- AbarelixExisting use: Neoplasm67.7% AI-predicted activityagainst MRSA5 registered studies
- EverolimusExisting use: Adenoma sebaceum, Anaplastic astrocytoma, Angiomyolipoma and 18 more67.5% AI-predicted activityagainst MRSA50+ registered studies
- Paliperidone PalmitateExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.3% AI-predicted activityagainst MRSA50+ registered studies
- PaliperidoneExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.2% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia
NCT07674810 · start 2026-12-31
Registered record
- Registry ID
- NCT07674810
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Zanubrutinib; Obinutuzumab; Sonrotoclax
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Not yet recruiting
- Start
- 2026-12-31
- Completion
- 2029-04-30
- Enrolment
- 40
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionChronic Lymphocytic LeukemiaInterventionZanubrutinib; Obinutuzumab; SonrotoclaxPhasePhase 2Registry statusNot yet recruitingVenetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
NCT07734038 · start 2026-10-01
Registered record
- Registry ID
- NCT07734038
- Conditions
- Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
- Interventions
- Biospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Computed Tomography; Magnetic Resonance Imaging; Venetoclax; Zanubrutinib
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Recruiting
- Start
- 2026-10-01
- Completion
- 2027-12-31
- Enrolment
- 155
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionChronic Lymphocytic Leukemia; Small Lymphocytic LymphomaInterventionBiospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Computed Tomography +3 morePhasePhase 2Registry statusRecruitingA Study of Zanubrutinib, Obinutuzumab, and Sonrotoclax in People With Mantle Cell Lymphoma
NCT07799220 · start 2026-09
Registered record
- Registry ID
- NCT07799220
- Conditions
- Mantle Cell Lymphoma
- Interventions
- Zanubrutinib; Obinutuzumab; Sonrotoclax
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Not yet recruiting
- Start
- 2026-09
- Completion
- 2028-09
- Enrolment
- 45
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMantle Cell LymphomaInterventionZanubrutinib; Obinutuzumab; SonrotoclaxPhasePhase 2Registry statusNot yet recruitingAI-Driven Treatment Strategy vs ZR2 in Older Treatment-naive Patients With LBCL
NCT07717177 · start 2026-06-30
Registered record
- Registry ID
- NCT07717177
- Conditions
- Large B-Cell Lymphoma (LBCL)
- Interventions
- Polatuzumab Vedotin; Rituximab (R); Zanubrutinib; Lenalidomide; Glofitamab
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Not yet recruiting
- Start
- 2026-06-30
- Completion
- 2029-12-31
- Enrolment
- 112
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLarge B-Cell Lymphoma (LBCL)InterventionPolatuzumab Vedotin; Rituximab (R); Zanubrutinib; Lenalidomide +1 morePhasePhase 2Registry statusNot yet recruitingA Study of MRD-Guided Zanubrutinib Plus Sonrotoclax in Treatment-Naïve, High-Risk CLL/SLL Patients
NCT07671378 · start 2026-06-01
Registered record
- Registry ID
- NCT07671378
- Conditions
- CLL (Chronic Lymphocytic Leukemia)
- Interventions
- Zanubrutinib and sonrotoclax
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Recruiting
- Start
- 2026-06-01
- Completion
- 2030-12-31
- Enrolment
- 24
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCLL (Chronic Lymphocytic Leukemia)InterventionZanubrutinib and sonrotoclaxPhasePhase 2Registry statusRecruitingEfficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma
NCT07418190 · start 2026-02-01
Registered record
- Registry ID
- NCT07418190
- Conditions
- Relapsed/Refractory Follicular Lymphoma
- Interventions
- tislelizumab + zanubrutinib + rituximab + lenalidomide
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Recruiting
- Start
- 2026-02-01
- Completion
- 2029-12-31
- Enrolment
- 33
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRelapsed/Refractory Follicular LymphomaInterventiontislelizumab + zanubrutinib + rituximab + lenalidomidePhasePhase 2Registry statusRecruitingA Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
NCT07277231 · start 2026-01-22
Registered record
- Registry ID
- NCT07277231
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Sonrotoclax; Zanubrutinib; Acalabrutinib; Venetoclax
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Recruiting
- Start
- 2026-01-22
- Completion
- 2031-11
- Enrolment
- 500
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionChronic Lymphocytic LeukemiaInterventionSonrotoclax; Zanubrutinib; Acalabrutinib; VenetoclaxPhasePhase 3Registry statusRecruitingMosunetuzumab for CLL MRD Clearance
NCT07052695 · start 2025-11-24
Registered record
- Registry ID
- NCT07052695
- Conditions
- Leukemia; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Lymphoma
- Interventions
- Mosunetuzumab; Ibrutinib; Acalabrutinib; Zanubrutinib; Pirtobrutinib
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Recruiting
- Start
- 2025-11-24
- Completion
- 2032-12-31
- Enrolment
- 40
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLeukemia; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; LymphomaInterventionMosunetuzumab; Ibrutinib; Acalabrutinib; Zanubrutinib +1 morePhasePhase 1 / Phase 2Registry statusRecruitingApplication of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell Lymphoma
NCT07371923 · start 2025-11-20
Registered record
- Registry ID
- NCT07371923
- Conditions
- Diffuse Large B Cell Lymphoma (DLBCL)
- Interventions
- Zanubrutinib+Pola-R-CHP
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Recruiting
- Start
- 2025-11-20
- Completion
- 2028-08-31
- Enrolment
- 50
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDiffuse Large B Cell Lymphoma (DLBCL)InterventionZanubrutinib+Pola-R-CHPPhasePhase 2Registry statusRecruitingSKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)
NCT07021495 · start 2025-07-29
Registered record
- Registry ID
- NCT07021495
- Conditions
- Chronic Spontaneous Urticaria (CSU); Hidradenitis Suppurativa (HS); Psoriasis (PsO); Atopic Dermatitis (AD); CTCL/ Mycosis Fungoides
- Interventions
- Not recorded
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Recruiting
- Start
- 2025-07-29
- Completion
- 2029-12-31
- Enrolment
- 840
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionChronic Spontaneous Urticaria (CSU); Hidradenitis Suppurativa (HS); Psoriasis (PsO); Atopic Dermatitis (AD) +1 moreInterventionNot recordedPhaseNot recordedRegistry statusRecruitingA Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T
NCT06167785 · start 2025-06-04
Registered record
- Registry ID
- NCT06167785
- Conditions
- Large B-cell Lymphoma
- Interventions
- Tislelizumab; Zanubrutinib; Tislelizumab + Zanubrutinib
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Recruiting
- Start
- 2025-06-04
- Completion
- 2029-12
- Enrolment
- 76
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLarge B-cell LymphomaInterventionTislelizumab; Zanubrutinib; Tislelizumab + ZanubrutinibPhasePhase 2Registry statusRecruitingZanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL
NCT06849713 · start 2025-05-16
Registered record
- Registry ID
- NCT06849713
- Conditions
- Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma (SLL)
- Interventions
- Zanubrutinib; Sonrotoclax; Obinutuzumab; Tacabrutideg
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Recruiting
- Start
- 2025-05-16
- Completion
- 2030-03-01
- Enrolment
- 80
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionChronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma (SLL)InterventionZanubrutinib; Sonrotoclax; Obinutuzumab; TacabrutidegPhasePhase 2Registry statusRecruitingZanubrutinib Plus GCVP (Obinutuzumab, Cyclophosphamide, Vindesine, Prednisolone) in Previously Untreated Follicular Lymphoma
NCT06918015 · start 2025-05-01
Registered record
- Registry ID
- NCT06918015
- Conditions
- BTK Inhibitors; Follicular Lymphoma; Immunochemotherapy
- Interventions
- ZGCVP
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Not yet recruiting
- Start
- 2025-05-01
- Completion
- 2030-05-01
- Enrolment
- 58
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBTK Inhibitors; Follicular Lymphoma; ImmunochemotherapyInterventionZGCVPPhasePhase 2Registry statusNot yet recruitingBRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma
NCT06854003 · start 2025-04-22
Registered record
- Registry ID
- NCT06854003
- Conditions
- Mantle Cell Lymphoma; Lymphoma
- Interventions
- Bendamustine; Rituximab; Cytarabine; Zanubrutinib; Sonrotoclax
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Recruiting
- Start
- 2025-04-22
- Completion
- 2039-11-01
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMantle Cell Lymphoma; LymphomaInterventionBendamustine; Rituximab; Cytarabine; Zanubrutinib +1 morePhasePhase 2Registry statusRecruitingA Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
NCT06697184 · start 2025-01-23
Registered record
- Registry ID
- NCT06697184
- Conditions
- Chronic Lymphocytic Leukemia; CLL; Mantle Cell Lymphoma; MCL
- Interventions
- Sonrotoclax; Zanubrutinib
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Recruiting
- Start
- 2025-01-23
- Completion
- 2032-11-30
- Enrolment
- 258
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionChronic Lymphocytic Leukemia; CLL; Mantle Cell Lymphoma; MCLInterventionSonrotoclax; ZanubrutinibPhasePhase 1 / Phase 2Registry statusRecruiting